MELBOURNE, Australia and INDIANAPOLIS, April 07, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, “Telix”) provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026).
Q1 2026 Highlights
- Q1 2026 unaudited Group revenue of US$230 million, up 11% quarter-over-quarter.
- FY 2026 revenue guidance of US$950 million to US$970 million is reaffirmed.
- Precision Medicine Q1 2026 unaudited revenue of US$186 million, up 16% quarter-over-quarter. Strong revenue growth in both Illuccix® and Gozellix® segments.
- ProstACT® Global Phase 3 study of TLX591-Tx prostate cancer therapy candidate: Part 1 lead-in met safety and dosimetry objectives, with no new safety signals observed1.
- TLX101-Px (brain cancer imaging candidate): New Drug Application (NDA) resubmitted to the United States (U.S.) Food and Drug Administration (FDA)2 for Pixclara®3. Marketing Authorization Application (MAA) filed in Europe4 for Pixlumi®3.
- TLX591-Px5: NDA accepted in China by the National Medical Products Administration (NMPA)6.
Q1 2026 Revenue (Unaudited)
| Revenue (US$M) | Q1 2026 | Q1 2025 | Variation | Q4 2025 | Variation |
| Group revenue | 230 | 186 | 24% | 208 | 11% |
| Precision Medicine revenue7 | 186 | 151 | 23% | 161 | 16% |
| TMS third-party revenue8 | 44 | 34 | 29% | 44 | —% |
Executive Commentary
Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, “Growth accelerated across our Precision Medicine business in the first quarter, with U.S. dose volumes increasing 5% quarter-over-quarter. This performance reflects the growing uptake of Gozellix alongside Illuccix, contributing to market share gains underpinned by disciplined sales execution and pricing, and high-quality service delivery despite extreme North American weather conditions, an advantage of the pharmacy distribution model. With our two‑product PSMA9 imaging strategy, differentiated clinical positioning and expanding commercial presence globally, we are seeing a solid foundation for continued growth through 2026. Importantly, we are delivering on our strategic priorities to advance our high-value clinical programs, demonstrated by the momentum …